A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder

Robert G. Voigt, Antolin Llorente, Craig L. Jensen, J. Kennard Fraley, Marcia C. Berretta, William C. Heird

Research output: Contribution to journalArticle

238 Citations (Scopus)

Abstract

Objective: To determine whether docosahexaenoic acid (DHA) supplementation for 4 months decreases the symptoms of attention-deficit/hyperactivity disorder (ADHD). Study design: Sixty-three 6- to-12-year-old children with ADHD, all receiving effective maintenance therapy with stimulant medication, were assigned randomly, in a double-blind fashion, to receive DHA supplementation (345 mg/d) or placebo for 4 months. Outcome variables included plasma phospholipid fatty acid patterns, scores on laboratory measures of inattention and impulsivity (Test of Variables of Attention, Children's Color Trails test) while not taking stimulant medication, and scores on parental behavioral rating scales (Child Behavior Checklist, Conners' Rating Scale). Differences between groups after 4 months of DHA supplementation or placebo administration were determined by analysis of variance, controlling for age, baseline value of each outcome variable, ethnicity, and ADHD subtype. Results: Plasma phospholipid DHA content of the DHA-supplemented group was 2.6-fold higher at the end of the study than that of the placebo group (4.85 ± 1.35 vs 1.86 ± 0.87 mol % of total fatty acids; P < .001). Despite this, there was no statistically significant improvement in any objective or subjective measure of ADHD symptoms. Conclusion: A 4-month period of DHA supplementation (345 mg/d) does not decrease symptoms of ADHD.

Original languageEnglish (US)
Pages (from-to)189-196
Number of pages8
JournalJournal of Pediatrics
Volume139
Issue number2
DOIs
StatePublished - Jan 1 2001

Fingerprint

Docosahexaenoic Acids
Attention Deficit Disorder with Hyperactivity
Placebos
Phospholipids
Fatty Acids
Impulsive Behavior
Child Behavior
Checklist
Analysis of Variance
Color

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Voigt, Robert G. ; Llorente, Antolin ; Jensen, Craig L. ; Fraley, J. Kennard ; Berretta, Marcia C. ; Heird, William C. / A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. In: Journal of Pediatrics. 2001 ; Vol. 139, No. 2. pp. 189-196.
@article{717cd34ab293465db0c58bf16973c211,
title = "A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder",
abstract = "Objective: To determine whether docosahexaenoic acid (DHA) supplementation for 4 months decreases the symptoms of attention-deficit/hyperactivity disorder (ADHD). Study design: Sixty-three 6- to-12-year-old children with ADHD, all receiving effective maintenance therapy with stimulant medication, were assigned randomly, in a double-blind fashion, to receive DHA supplementation (345 mg/d) or placebo for 4 months. Outcome variables included plasma phospholipid fatty acid patterns, scores on laboratory measures of inattention and impulsivity (Test of Variables of Attention, Children's Color Trails test) while not taking stimulant medication, and scores on parental behavioral rating scales (Child Behavior Checklist, Conners' Rating Scale). Differences between groups after 4 months of DHA supplementation or placebo administration were determined by analysis of variance, controlling for age, baseline value of each outcome variable, ethnicity, and ADHD subtype. Results: Plasma phospholipid DHA content of the DHA-supplemented group was 2.6-fold higher at the end of the study than that of the placebo group (4.85 ± 1.35 vs 1.86 ± 0.87 mol {\%} of total fatty acids; P < .001). Despite this, there was no statistically significant improvement in any objective or subjective measure of ADHD symptoms. Conclusion: A 4-month period of DHA supplementation (345 mg/d) does not decrease symptoms of ADHD.",
author = "Voigt, {Robert G.} and Antolin Llorente and Jensen, {Craig L.} and Fraley, {J. Kennard} and Berretta, {Marcia C.} and Heird, {William C.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1067/mpd.2001.116050",
language = "English (US)",
volume = "139",
pages = "189--196",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "2",

}

A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. / Voigt, Robert G.; Llorente, Antolin; Jensen, Craig L.; Fraley, J. Kennard; Berretta, Marcia C.; Heird, William C.

In: Journal of Pediatrics, Vol. 139, No. 2, 01.01.2001, p. 189-196.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder

AU - Voigt, Robert G.

AU - Llorente, Antolin

AU - Jensen, Craig L.

AU - Fraley, J. Kennard

AU - Berretta, Marcia C.

AU - Heird, William C.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Objective: To determine whether docosahexaenoic acid (DHA) supplementation for 4 months decreases the symptoms of attention-deficit/hyperactivity disorder (ADHD). Study design: Sixty-three 6- to-12-year-old children with ADHD, all receiving effective maintenance therapy with stimulant medication, were assigned randomly, in a double-blind fashion, to receive DHA supplementation (345 mg/d) or placebo for 4 months. Outcome variables included plasma phospholipid fatty acid patterns, scores on laboratory measures of inattention and impulsivity (Test of Variables of Attention, Children's Color Trails test) while not taking stimulant medication, and scores on parental behavioral rating scales (Child Behavior Checklist, Conners' Rating Scale). Differences between groups after 4 months of DHA supplementation or placebo administration were determined by analysis of variance, controlling for age, baseline value of each outcome variable, ethnicity, and ADHD subtype. Results: Plasma phospholipid DHA content of the DHA-supplemented group was 2.6-fold higher at the end of the study than that of the placebo group (4.85 ± 1.35 vs 1.86 ± 0.87 mol % of total fatty acids; P < .001). Despite this, there was no statistically significant improvement in any objective or subjective measure of ADHD symptoms. Conclusion: A 4-month period of DHA supplementation (345 mg/d) does not decrease symptoms of ADHD.

AB - Objective: To determine whether docosahexaenoic acid (DHA) supplementation for 4 months decreases the symptoms of attention-deficit/hyperactivity disorder (ADHD). Study design: Sixty-three 6- to-12-year-old children with ADHD, all receiving effective maintenance therapy with stimulant medication, were assigned randomly, in a double-blind fashion, to receive DHA supplementation (345 mg/d) or placebo for 4 months. Outcome variables included plasma phospholipid fatty acid patterns, scores on laboratory measures of inattention and impulsivity (Test of Variables of Attention, Children's Color Trails test) while not taking stimulant medication, and scores on parental behavioral rating scales (Child Behavior Checklist, Conners' Rating Scale). Differences between groups after 4 months of DHA supplementation or placebo administration were determined by analysis of variance, controlling for age, baseline value of each outcome variable, ethnicity, and ADHD subtype. Results: Plasma phospholipid DHA content of the DHA-supplemented group was 2.6-fold higher at the end of the study than that of the placebo group (4.85 ± 1.35 vs 1.86 ± 0.87 mol % of total fatty acids; P < .001). Despite this, there was no statistically significant improvement in any objective or subjective measure of ADHD symptoms. Conclusion: A 4-month period of DHA supplementation (345 mg/d) does not decrease symptoms of ADHD.

UR - http://www.scopus.com/inward/record.url?scp=0034906106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034906106&partnerID=8YFLogxK

U2 - 10.1067/mpd.2001.116050

DO - 10.1067/mpd.2001.116050

M3 - Article

C2 - 11487742

AN - SCOPUS:0034906106

VL - 139

SP - 189

EP - 196

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 2

ER -